Home News

News

The sign I Amsterdam in front of rijksmuseum in Amsterdam, The Netherlands.

Sutro Presents Preliminary Results From Ongoing Phase I Study of STRO-001

California-based Sutro Biopharma has confirmed that the company will present preliminary results from the first 14 patients enrolled in...
Magazines heap detail

Site Specific Conjugation of Hydrophobic Payloads Without Genetic Engineering

Site-specific conjugation leads to more homogeneous conjugates and allows control of the site of drug attachment. This approach frequently...

ImmunoGen and FDA Discuss Ongoing Development for Mirvetuximab Soravtansine

The United States Food and Drug Administration (FDA) has recommended that ImmunoGen conducts a new Phase III randomized trial...

Zymeworks Signs Licensing Agreement with Iconic Therapeutics

Canada-based Zymeworks, a clinical-stage biopharmaceutical company, has entered into a licensing agreement that grants Iconic Therapeutics non-exclusive rights to...
Featured Photo: Attendees during the Plenary Session at the American Society for Clinical Oncology (ASCO) Annual Meeting Photo Courtesy: ASCO/Scott Morgan.

Alligator Bioscience to Present Clinical Data from ADC-1013 Phase I Study

Data from a Phase I Clinical Study of ADC-1013 (Alligator Bioscience) will be presented at the upcoming annual meeting...

Immunomedics and Everest Signs License Agreement for Sacituzumab Govitecan

In late April 2019 Immunomedics and Everest Medicines II Limited, a C-Bridge Capital-backed biopharmaceutical company, confirmed that the companies...

ADC Therapeutics and Adagene Enter into a Discovery Collaboration and License Agreement

ADC Therapeutics, headquartered in Lausanne, Switzerland, and Adagene, a clinical stage biotech company based in Suzhou, China and San...
Featured Image: Doctor explaining diagnosis to her patient Courtesy: © 2017 Fotolia. Used with permission.

Triphase’s TRPH-222, a Site-specific Anti-CD22 ADC, Enters Clinical Phase I Trials

Triphase Accelerator, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the...

Dutch Biotech Signs License Agreement with Chinese ADC Developer

The Dutch biotech company Synaffix has signed a license agreement with the Chinese ADC developer Shanghai Miracogen. The agreement...

WuXi Biologics and NBE-Therapeutics Collaborate in Development and Manufacturing Partnership

WuXi Biologics, an open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Swiss...